Expanding its footprint in vaccine business, GlaxoSmithKline (GSK) has agreed to partner with CureVac to develop and commercialise up to five mRNA-based vaccines and monoclonal antibodies targeting infectious diseases. The deal, which is worth up to £866 M, complements GSK’s self-amplifying mRNA technology and aligns with the company’s commitment to vaccine development. A day after the GSK deal was announced, CureVac closed a private financing round which raised US$640 M.